Toxicogenomics can change face of clinical trials

“Genomics is only the start. Proteomics has been around for years and metabonomics is an up and coming important technology, both of which are complimentary to genomics. But still I think that genomics will be the most successful and most predictive of all these technologies.” Dr Phil Hewitt  Head of Toxicogenomics at Merck.

Meanwhile Gene Logic Provides the FDA with Access to Toxicogenomics Data and Analysis Systems for Reviewing Voluntary Genomic Data Submissions, and Iconix Released On-Line Version of World’s Largest Toxicogenomic Reference Database ,

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: